vs
Riley Exploration Permian, Inc.（REPX）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Riley Exploration Permian, Inc.的1.3倍（$127.1M vs $97.3M），再鼎医药同比增速更快（17.1% vs -5.3%），过去两年再鼎医药的营收复合增速更高（20.8% vs -1.2%）
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
REPX vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.3倍
$97.3M
营收增速更快
ZLAB
高出22.4%
-5.3%
两年增速更快
ZLAB
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $97.3M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 26.9% | -54.6% |
| 净利率 | — | — |
| 营收同比 | -5.3% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $4.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REPXZLAB
| Q4 25 | $97.3M | $127.1M | ||
| Q3 25 | $106.9M | $115.4M | ||
| Q2 25 | $85.4M | $109.1M | ||
| Q1 25 | $102.5M | $105.7M | ||
| Q4 24 | $102.7M | $108.5M | ||
| Q3 24 | $102.3M | $101.8M | ||
| Q2 24 | $105.4M | $100.1M | ||
| Q1 24 | $99.7M | $87.1M |
净利润REPXZLAB
| Q4 25 | — | — | ||
| Q3 25 | $16.3M | $-36.0M | ||
| Q2 25 | $30.5M | $-40.7M | ||
| Q1 25 | $28.6M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $25.7M | $-41.7M | ||
| Q2 24 | $33.5M | $-80.3M | ||
| Q1 24 | $18.8M | $-53.5M |
毛利率REPXZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率REPXZLAB
| Q4 25 | 26.9% | -54.6% | ||
| Q3 25 | 27.0% | -42.3% | ||
| Q2 25 | 33.7% | -50.3% | ||
| Q1 25 | 48.3% | -53.3% | ||
| Q4 24 | 31.2% | -62.6% | ||
| Q3 24 | 17.1% | -66.6% | ||
| Q2 24 | 50.9% | -76.0% | ||
| Q1 24 | 50.7% | -80.7% |
净利率REPXZLAB
| Q4 25 | — | — | ||
| Q3 25 | 15.3% | -31.2% | ||
| Q2 25 | 35.7% | -37.3% | ||
| Q1 25 | 27.9% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.1% | -40.9% | ||
| Q2 24 | 31.8% | -80.2% | ||
| Q1 24 | 18.8% | -61.4% |
每股收益（稀释后）REPXZLAB
| Q4 25 | $4.02 | $-0.05 | ||
| Q3 25 | $0.77 | $-0.03 | ||
| Q2 25 | $1.44 | $-0.04 | ||
| Q1 25 | $1.36 | $-0.04 | ||
| Q4 24 | $0.52 | $-0.09 | ||
| Q3 24 | $1.21 | $-0.04 | ||
| Q2 24 | $1.59 | $-0.08 | ||
| Q1 24 | $0.94 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $247.9M | — |
| 股东权益账面价值 | $634.2M | $715.5M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.39× | — |
8季度趋势，按日历期对齐
现金及短期投资REPXZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务REPXZLAB
| Q4 25 | $247.9M | — | ||
| Q3 25 | $367.0M | — | ||
| Q2 25 | $275.2M | — | ||
| Q1 25 | $249.3M | — | ||
| Q4 24 | $269.5M | — | ||
| Q3 24 | $288.6M | — | ||
| Q2 24 | $322.7M | — | ||
| Q1 24 | $341.8M | — |
股东权益REPXZLAB
| Q4 25 | $634.2M | $715.5M | ||
| Q3 25 | $566.5M | $759.9M | ||
| Q2 25 | $556.9M | $791.7M | ||
| Q1 25 | $532.4M | $810.8M | ||
| Q4 24 | $510.6M | $840.9M | ||
| Q3 24 | $507.4M | $667.7M | ||
| Q2 24 | $489.0M | $704.2M | ||
| Q1 24 | $434.6M | $762.2M |
总资产REPXZLAB
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $994.9M | $1.2B | ||
| Q4 24 | $993.5M | $1.2B | ||
| Q3 24 | $997.9M | $985.3M | ||
| Q2 24 | $1.0B | $987.4M | ||
| Q1 24 | $956.4M | $988.4M |
负债/权益比REPXZLAB
| Q4 25 | 0.39× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $64.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流REPXZLAB
| Q4 25 | $64.9M | $-26.0M | ||
| Q3 25 | $63.6M | $-32.0M | ||
| Q2 25 | $33.6M | $-31.0M | ||
| Q1 25 | $50.4M | $-61.7M | ||
| Q4 24 | $66.4M | $-55.8M | ||
| Q3 24 | $72.1M | $-26.8M | ||
| Q2 24 | $51.6M | $-42.2M | ||
| Q1 24 | $56.1M | $-90.1M |
自由现金流REPXZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率REPXZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度REPXZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率REPXZLAB
| Q4 25 | — | — | ||
| Q3 25 | 3.90× | — | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.81× | — | ||
| Q2 24 | 1.54× | — | ||
| Q1 24 | 2.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REPX
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
